(HIBS) Direxion Daily SP500 High - Overview
Etf: Inverse, Triple, Leveraged, ETF
Dividends
| Dividend Yield | 4.02% |
| Yield on Cost 5y | 0.21% |
| Yield CAGR 5y | 248.98% |
| Payout Consistency | 50.5% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 74.0% |
| Relative Tail Risk | -6.10% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.02 |
| Alpha | -27.39 |
| Character TTM | |
|---|---|
| Beta | -4.428 |
| Beta Downside | -4.449 |
| Drawdowns 3y | |
|---|---|
| Max DD | 92.58% |
| CAGR/Max DD | -0.57 |
Description: HIBS Direxion Daily SP500 High December 23, 2025
Direxion Daily S&P 500® High Beta Bear 3X Shares (HIBS) seeks to deliver three times the inverse daily performance of a basket of the 100 S&P 500 stocks with the highest historical beta. To meet this goal, the fund must allocate at least 80 % of its net assets to derivatives-such as swaps, futures, and options-that together provide the targeted 3× short exposure. Because the strategy relies on daily re-balancing, returns compound path-dependently and the ETF is classified as non-diversified.
Key quantitative points to watch: (1) the fund’s expense ratio sits around 0.95 %, which is higher than typical passive ETFs but common for leveraged, inverse products; (2) its 30-day implied volatility typically exceeds 70 % during market stress, reflecting the amplified risk of a 3× short position; and (3) performance is highly sensitive to macro drivers such as U.S. interest-rate policy and equity market volatility (VIX), since higher rates can increase the cost of financing derivatives and a rising VIX often boosts the beta-heavy stocks that HIBS shorts. Investors should also note that the fund’s beta-adjusted exposure can diverge sharply from a simple 3× inverse of the S&P 500 over longer horizons due to compounding effects.
For a deeper dive into how HIBS behaves across different market regimes, you might explore the ValueRay platform’s back-tested scenario analysis tools.
What is the price of HIBS shares?
Over the past week, the price has changed by -2.55%, over one month by -6.25%, over three months by -24.04% and over the past year by -73.43%.
Is HIBS a buy, sell or hold?
What are the forecasts/targets for the HIBS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 3.4 | -20% |
HIBS Fundamental Data Overview February 02, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 20.1m USD (20.1m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 20.1m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 20.1m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = -10.40% (negative - check inputs) (E(20.1m)/V(20.1m) * Re(-10.40%) + (debt-free company))
Discount Rate = 9.60% (= Risk Free + ERP)
Fair Price DCF = unknown (Cash Flow 0.0)